Immunotherapy platform targeting chronic pain mediators

Overview

The immunotherapy platform is a pioneering therapeutic-vaccine technology developed over a decade to treat chronic pain and inflammation in companion animals, including dogs, cats, and horses. By utilizing recombinant fusion proteins, the platform actively stimulates the immune system to produce antibodies that neutralize multiple endogenous nociceptive (pain-mediating) factors, such as nerve growth factor (NGF) and substance P (SP) or calcitonin gene-related peptide (CGRP). This multi-valent approach blocks specific pain pathways more effectively than traditional single-target therapies, providing a long-lasting, safe, and disruptive alternative for managing conditions like osteoarthritis, neuropathic pain, and cancer-associated pain.

Technical specifications

• Multi-valent Immunogens: Employs recombinant fusion proteins that simultaneously target two or more pain mediators to achieve synergistic therapeutic effects.
• Mechanism: The vaccine triggers the production of neutralizing antibodies that intercept pain signals at their source, reducing both pain intensity and the requirement for traditional, often side-effect-prone, anti-inflammatory medications.
• Veterinary Applications: Designed for the treatment of osteoarthritis, chronic neuroinflammation, neuropathic lesions, and cancer-related pain in canine, feline, and equine patients.
• Manufacturing: The platform utilizes validated recombinant protein expression systems and GMP-quality production standards to ensure safety, efficacy, and consistency.
• Clinical Status: Lead products, such as Xep01, have demonstrated safety, tolerability, and efficacy in reducing pain and improving mobility in laboratory and clinical trials.

Technology readiness level

7, Based on the successful production of GMP-quality vaccine batches, completion of pilot safety trials, and ongoing clinical evaluation of lead assets in companion animals.